NEOPHYR 450 PPM MOL/MOL MEDICINAL GAS COMPRESSED - patient leaflet, side effects, dosage

Neophyr

Neophyr

225 ppm mol/mol

450 ppm mol/mol

1000 ppm mol/mol

Medicinal gas, compressed

Nitric oxide

225 ppm, 450 ppm, 1000 ppm mol/mol

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

• 1. What Neophyr is and what it is used for

• 2. What you need to know before you use Neophyr

• 3. How to use Neophyr

• 4. Possible side effects

• 5. How to store Neophyr

• 6. Contents of the pack and other information

1. what neophyr is and what it is used for

Neophyr is a gas mixture for inhalation use. Neophyr is a medicinal gas, compressed, consisting of a mixture of gases that contains 225 ppm, 450 ppm or 1000 ppm mol/mol of nitric oxide.

What are its uses?

Neophyr must be administered exclusively by healthcare professionals and it is only for strict hospital use.

Neophyr is indicated in the following conditions:

• newborn babies with lung failure associated with high blood pressure in the lungs, a condition known as hypoxic respiratory failure. When inhaled, this gas mixture can improve the flow of blood through the lungs, which may help to increase the amount of oxygen that reaches your baby’s blood.
• newborn babies, babies, children, teenagers 0–17 years and adults with high blood pressure in the lungs, connected with heart surgery. This gas mixture can improve heart function and increase the flow of blood through the lungs.

2. what you need to know before you use neophyr

Do not use Neophyr

• If you (as the patient) or your child (as the patient) are allergic (hypersensitive) to nitric oxide or any of the other ingredients of this medicine (listed in section 6).
• If you have been told that you (as the patient) or your child (as the patient) have an abnormal circulation within the heart.
• If you (as the patient) or your child (as the patient) have congenital or acquired deficiency of methemoglobin reductase (MetHb reductase) or glucose 6 phosphate dehydrogenase (G6PD).

Warnings and precautions

Talk to your doctor before using Neophyr.

Inhaled nitric oxide may not always be effective and thus other therapies may be considered necessary for you or your child.

Inhaled nitric oxide may influence the oxygen carrying capacity of the blood. This will be monitored by blood samples and if required the dose of inhaled nitric oxide must be reduced.

Nitric oxide may react with oxygen forming nitrogen dioxide that may cause airway irritation. Your or your child’s doctor will undertake monitoring of nitrogen dioxide and in case of elevated values the Neophyr therapy will be adjusted, decreased accordingly. Inhaled nitric oxide may have a mild but influence on the platelets (components that help the blood to clot) of you or your child and any signs of bleeding and or haematoma should be observed. If you see any signs or symptoms that may be associated to bleeding you should directly inform the doctor. No effect of inhaled nitric has been documented in newborn babies with a malformation where the diaphragm is not fully complete, so called ‘congenital diaphragmatic hernia’.

In newborn babies with special malformations of the heart, ‘what doctors calls congenital heart defects’ inhaled nitric oxide may cause a worsening of the circulation.

Children

Neophyr should not be used in preterm baby < 34 weeks of gestational age.

Other medicines and Neophyr

The doctor will decide when to treat you or your child with Neophyr and with other medicines, and will carefully supervise the treatment.

Tell your doctor if you (as the patient) or your child (as the patient) are taking, have recently taken or might take any other medicines.

Some medicines can affect the ability of blood to carry oxygen. These include prilocaine (a local anaesthetic used for pain relief in association to minor painful procedures e.g. suturing, and minor surgical or diagnostic procedures) or glyceryl trinitrate (used to treat chest pain). Your doctor will take care to check that the blood can carry enough oxygen when you are taken these medicines.

Pregnancy, breast-feeding and fertility

Neophyr should not be used during pregnancy unless clearly necessary, such as in situations of life support. Exposure to nitric oxide in humans during lactation should be avoided. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

3. how to use neophyr

Your doctor will decide the correct dose of Neophyr and will administer Neophyr to you or your child’s lungs through a system designed for delivering this gas. This delivery system will ensure that the correct amount of nitric oxide is delivered by diluting Neophyr with an oxygen/air mixture immediately before giving it to you.

For you or your child’s safety, the delivery systems intended for administration of Neophyr are fitted with devices that constantly measure the amount of nitric oxide, oxygen and nitrogen dioxide (a chemical formed when nitric oxide and oxygen are mixed) being delivered to the lungs.

Your doctor will decide how long you or your child should be treated with Neophyr.

Neophyr is given in dose of 10 to 20 ppm, (maximal dose 20 ppm in children and 40 ppm in adults) parts per million of the gas that you or your child inhale. The lowest effective dose will be sought. Therapy is usually required for about 4 days in newborn infants with lung failure associated with high blood pressure in the lungs. In children and adults with high blood pressure in the lungs, connected with heart surgery, Neophyr is usually given for 24–48 hours. However, therapy with Neophyr may last longer.

If you receive more Neophyr than you should

Too much of inhaled nitric oxide may influence the oxygen carrying capacity of the blood. This will be monitored by blood samples and if required the Neophyr dose will be decreased and the administration of medicines such as vitamin C, methylene blue, or eventually blood transfusion, in order to improve the oxygen carrying capacity, may be considered.

If you stop receiving Neophyr

Treatment with Neophyr should not be stopped suddenly. Low blood pressure or a rebound increase in pressure in the lungs has been known to occur if treatment with Neophyr is stopped suddenly without first lowering the dose. At the end of treatment, the doctor will slowly lower the amount of Neophyr being given to you or your child, so that the circulation in the lungs is able to adjust to oxygen/air without Neophyr. Thus it may take a day or two before you or your child is off Neophyr therapy.

If you have any further questions on the use of this medicine ask your doctor or other healthcare professionals.

4. possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will notice and closely monitor any side effects. It is not likely that you will experience these side effects yourself.

Side effects that are very commonly seen (affects more than 1 user in 10) in association with Neophyr therapy include:

• Low platelet count, abnormally low potassium concentration in the blood (hypokalemia), low blood pressure, airless or collapsed lung, abnormally high amounts of bile pigment (bilirubin) in the blood.

Side effects that may be seen but the frequency is not known (frequency cannot be estimated from the available data) are:

• Rebound high blood pressure in the lungs (increase in pulmonary artery pressure), and too low amount of oxygen in the blood (oxygen desaturation/hy­poxemia) due to sudden withdrawal of the treatment, increase in methemoglobin, thus reduced oxygen carrying capacity.
• Accidental ambient air exposure to nitric oxide, e.g. leakage from equipment or cylinder may cause headache.

You should directly inform the personnel if you experience headache while being in close proximity to your child receiving Neophyr.

If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

If you have any further questions on the use of this product ask your doctor or other healthcare professionals.

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme (Website: ).

By reporting side effects you can help provide more information on the safety of this medicine.

5. how to store neophyr

Keep this medicine out of the sight and reach of children.

Neophyr therapy should only be used and handled by hospital personnel.

• Neophyr cylinders should be stored secured in order to avoid falling and thus potentially causing harm.
• Neophyr should be used and administered only by personnel specially trained in the use and handling of Neophyr.

All regulations concerning handling of pressurised cylinders must be followed.

All regulations concerning handling of pressurised cylinders must be followed. Storage is supervised by specialists at the hospital. Gas cylinders are to be stored in well-ventilated rooms or in ventilated sheds where they are protected from rain and direct sunlight.

The cylinders must be stored at a temperature between –10 and +50°C.

Protect the cylinders from shocks, falls, oxidising and flammable materials, moisture, sources of heat or ignition.

Storage in the pharmacy department

The gas cylinders should be kept in a place designated exclusively for medicinal gas storage that is well ventilated, clean and under lock and key. This place should house a separate, special facility for the storage of nitric oxide gas cylinders.

Storage in medical department

The cylinder should be placed in an area with appropriate equipment to ensure that the cylinder is held vertically.

When the cylinder is empty, do not dispose of it. Empty cylinders will be collected by the supplier. Do not use this medicine after the expiry date which is stated on the gas cylinder label. The expiry date refers to the last day of that month.

6. contents of the pack and other informationwhat neophyr contains the active substance is nitric oxide

225 ppm mol/mol, 450 ppm mol/mol or 1000 ppm mol/mol

• The other ingredient is nitrogen

What Neophyr looks like and contents of the pack

Gas cylinders with a capacity of 2l (Neophyr 1000 ppm mol/mol).

A 2-liter gas cylinder filled to 150 bar contains about 0,35 kg of gas.

Or

Gas cylinders with a capacity of 10l (Neophyr 225 ppm mol/mol, Neophyr 450 ppm mol/mol, Neophyr 1000 ppm mol/mol).

A 10-liter gas cylinder filled to 150 bar contains about 1,77 kg of gas.

Aluminium alloy cylinders have a white painted body and a turquoise-painted shoulder.

They are equipped with a stainless steel residual pressure valve with a specific ISO 5145 (2004) type outlet connector.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

SOL SpA – via Borgazzi 27, 20900 Monza (Italy)

Manufacturer

SOL S.p.A. – via Liberta 247, 20900 Monza (Italy)

This medicinal product is authorized in the Member States of the EEA under the following names:

Austria: Neophyr

Belgium: Neophyr

Bulgaria: Neophyr

Croatia: Neophyr

Cyprus: Neophyr

Germany: Neophyr Greece: Neophyr Ireland: Neophyr Italy: Neophyr Luxemburg: Neophyr The Netherlands: Neophyr Romania: Neophyr Slovenia: Neophyr Spain: Neophyr United Kingdom: Neophyr

This leaflet was last revised in 07/2018.

Formation of methaemoglobin

A large portion of nitric oxide for inhalation is absorbed systemically. The end medicinal products of nitric oxide that enter the systemic circulation are predominantly methaemoglobin and nitrate. The concentrations of methaemoglobin in the blood should be monitored, see section 4.2.

Formation of NO 2

NO2 rapidly forms in gas mixtures containing nitric oxide and O2, and nitric oxide may in this way cause airway inflammation and damage. The dose of nitric oxide should be reduced if the concentration of nitrogen dioxide exceeds 0.5 ppm.

• 4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. A clinically significant interaction with other medicinal products used in the treatment of hypoxic respiratory failure cannot be excluded based on the available data.

Oxygen: In the presence of oxygen, nitric oxide oxidises rapidly forming derivatives that are toxic for the bronchiolar epithelium and the alveolo-capillar membrane. Nitrogen dioxide (NO2) is the main compound that is formed and may cause airway inflammation and damage. There are also animal data suggesting an increased susceptibility to airway infections upon exposure to low levels of NO2. During the treatment with nitric oxide, the concentration of NO2 must be < 0,5 ppm in the dose interval of < 20 ppm of nitric oxide. If, at any time, the concentration of NO2 exceeds 1 ppm, the dose of nitric oxide must be reduced immediately. See the information on monitoring NO2 in section 4.2.

NO donors: The donor compounds of nitric oxide, including sodium nitroprusside and nitroglycerine, can have an additive effect to Neophyr with regards to the risk of developing methaemoglobi­naemia.

Methaemoglobin inducers: There is a higher risk to develop methaemoglobinaemia if drugs that increase the methaemoglobin concentrations are administrated along with nitric oxide (e.g. alkyl nitrates, sulphonamides and prilocaine). As a consequence, medicinal products that increase methaemoglobin must be used with caution during inhaled nitric oxide therapy. Prilocaine, whether administered as oral, parenteral, or topical formulations may cause methaemoglobi­naemia. Care must be taken when Neophyr is given at the same time as medicinal products containing prilocaine. Synergic effects have been reported with the administration of vasoconstrictors (almitrine, phenylephrine), prostacyclin and phosphodiesterase inhibitors, without increasing adverse effects.

Inhaled nitric oxide has been used concomitantly with tolazoline, dopamine, dobutamine, steroids, surfactants and high frequency ventilation, with no drug interactions observed.

Experimental studies suggest that nitric oxide and also nitrogen dioxide can react chemically with the surfactant and its proteins without proven clinical consequences.

The combined used with other vasodilators (e.g. sildenafil) is not extensively studied. Available data suggest additive effects on central circulation, pulmonary artery pressure and right ventricular performance. Inhaled nitric oxide combination with other vasodilators acting by the cGMP or cAMP systems should be done with caution.

Although controlled studies have not been done, food interactions have not been noticed in clinical trials in patients with prolonged ambulatory administration.

• 4.6 Fertility, pregnancy and lactation

Fertility

No fertility studies have been performed.

Pregnancy

The effect of the administration of Neophyr in pregnant women is unknown. Animal studies are insufficient (see section 5.3).

The potential risk for humans is unknown. Neophyr should not be used during pregnancy unless clearly necessary, such as in situations of life support.

Breast-feeding

It is not known whether Neophyr passes into human breast milk. The excretion of Neophyr in milk has not been studied in animals. Exposure to nitric oxide in humans during lactation should be avoided.

• 4.7 Effects on ability to drive and use machines

Infants and hospitalized patient: Not relevant.

• 4.8 Undesirable effects

Summary of safety profile

Abrupt discontinuation of the administration of inhaled nitric oxide may cause rebound reaction; decrease in oxygenation and increase in central pressure and subsequent decrease in systemic blood pressure. Rebound reaction is the most commonly adverse reaction in association with the clinical use of Neophyr. The rebound may be seen early as well as late during therapy.

In one clinical study (NINOS), treatment groups were similar with respect to the incidence and severity of intracranial haemorrhage, Grade IV haemorrhage, periventricular leukomalacia, cerebral infarction, seizures requiring anticonvulsant therapy, pulmonary haemorrhage, or gastrointestinal haemorrhage. Tabulated list of adverse reactions The adverse reactions listed are derived from CINGRI study, review of public domain scientific literature and post marketing safety surveillance (the table below shows adverse reactions that occurred in at least 5% of patients receiving iNO in the CINRGI study). Adverse reactions are listed according to MedDRA frequency convention: very common (> 1/10), common (> 1/100 to <1/10), uncommon (> 1/1,000 to <1/100), rare (> 1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).

Description of selected adverse reactions Inhaled nitric oxide therapy may cause an increase in methaemoglobin.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme (Website: ).

• 4.9 Overdose

Overdose with Neophyr will be manifest by elevations in methaemoglobin and NO2. Elevated NO2 may cause acute lung injury. Elevations in methaemoglobinaemia reduce the oxygen delivery capacity of the circulation. In clinical studies, NO2 levels > 3 ppm or methaemoglobin levels > 7% were treated by reducing the dose of, or discontinuing, iNO. Methaemoglobinaemia that does not resolve after reduction or discontinuation of therapy can be treated with intravenous vitamin C, intravenous methylene blue, or blood transfusion, based upon the clinical situation.

• 5. PHARMACOLOGICAL PROPERTIES

  • 5.1 Pharmacody­namic properties

Nitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the haeme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3’,5’-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide produces selective pulmonary vasodilation. iNO appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better ventilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/per­fusion (V/Q) ratios toward regions with normal ratios. Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale. In neonates with PPHN, iNO can improve oxygenation (as indicated by significant increases in PaO2). The efficacy of iNO has been investigated in term and near-term newborns with hypoxic respiratory failure resulting from a variety of etiologies.

In the NINOS trial, 235 neonates with hypoxic respiratory failure were randomised to receive 100% O2 with (n=114) or without (n=121) nitric oxide most with an initial concentration of 20 ppm with weaning as possible to lower doses with a median duration of exposure of 40 hours. The objective of this double-blind, randomised, placebo controlled trial was to determine whether inhaled nitric oxide would reduce the occurrence of death and/or initiation of extracorporeal membrane oxygenation (ECMO). Neonates with less than a full response at 20 ppm were evaluated for a response to 80 ppm nitric oxide or control gas. The combined incidence of death and/or initiation of ECMO (the prospectively defined primary endpoint) showed a significant advantage for the nitric oxide treated group (46% vs. 64%, p=0.006). Data further suggested a lack of additional benefit for the higher dose of nitric oxide. The adverse events collected occurred at similar incidence rates in both groups. Follow-up exams at 18–24 months of age were similar between the two groups with respect to mental, motor, audiologic, and neurologic evaluations.

In the CINRGI trial, 186 term- and near-term neonates with hypoxic respiratory failure were randomised to receive either iNO (n=97) or nitrogen gas (placebo; n=89) with an initial dose of 20 ppm weaning to 5 ppm in 4 to 24 hours with median duration of exposure of 44 hours.

The prospectively defined primary endpoint was the receipt of ECMO. Significantly fewer neonates in the iNO group required ECMO compared to the control group (31% vs 57%, p<0.001).

The iNO group had significantly improved oxygenation as measured by PaO2, OI, and alveolar-arterial gradient (p<0.001 for all parameters). Of the 97 patients treated with , 2(2%) were withdrawn from study drug due to methaemoglobin levels >4%. The frequency and number of adverse events were similar in the two study groups.

In patients undergoing heart surgery, an increase in pulmonary artery pressure due to pulmonary vasoconstriction is frequently seen. Inhaled nitric oxide has been shown to selectively reduce pulmonary vascular resistance and reduce the increased pulmonary artery pressure. This may increase the right ventricular ejection fraction. These effects in turn lead to improved blood circulation and oxygenation in the pulmonary circulation.

In the INOT27 trial, 795 preterm infants (GA<29 weeks) with hypoxic respiratory failure were randomised to receive either iNO (n=395) in a dose of 5 ppm or nitrogen (placebo n=400), beginning within the first 24 hours of life and treated for at least 7 days, up to 21 days. The primary outcome, of the combined efficacy endpoints of death or BPD at 36 weeks GA, was not significantly different between groups, even with adjustment for gestational age as a covariate (p = 0.40), or with birth weight as a covariate (p = 0.41). The overall occurrence of intraventricular haemorrhage was 114 (28.9%) among the iNO treated as compared to 91 (22.9%) among the control neonates.

The overall number of death at week 36 was slightly higher in the iNO group; 53/395 (13.4%) as compared to control 42/397 (10.6%).

The INOT25 trial, studying the effects of iNO in hypoxic preterm neonates, did not show improvement in alive without BDP. No difference in the incidence of IVH or death was however observed in this study. The BALLR1 study, also evaluating the effects of iNO in preterm neonates, but initiating iNO at 7 days and in a dose of 20 ppm, found a significant increase in neonates alive without BPD at gestational week 36, 121 (45% vs 95 (35.4%) p<0.028. No signs of any increase adverse effects was noted in this study. Nitric oxide chemically reacts with oxygen to form nitrogen dioxide.

Nitric oxide has an unpaired electron, which makes the molecule reactive. In biological tissue, nitric oxide may form peroxynitrite with superoxide (O2 -), an unstable compound which may cause tissue damage through further redox reactions. In addition, nitric oxide has affinity to metalloproteins and may also react with SH-groups in protein forming nitrosyl compounds. The clinical significance of the chemical reactivity of nitric oxide in tissue is unknown. Studies show that nitric oxide exhibits pulmonary pharmacodynamic effects at intra-airway concentrations as low as 1 ppm. The European Medicines Agency has waived the obligation to submit the results of studies with iNO in all subsets of the paediatric population in persistent pulmonary hypertension and other pulmonary heart disease (see section 4.2 for information on paediatric use).

• 5.2 Pharmacoki­netic properties

The pharmacokinetics of nitric oxide has been studied in adults. Nitric oxide is absorbed systemically after inhalation. Most of it traverses the pulmonary capillary bed where it combines with haemoglobin that is 60% to 100% oxygen-saturated. At this level of oxygen saturation, nitric oxide combines predominantly with oxyhaemoglobin to produce methaemoglobin and nitrate. At low oxygen saturation, nitric oxide can combine with deoxyhaemoglobin to transiently form nitrosylhaemo­globin, which is converted to nitrogen oxides and methaemoglobin upon exposure to oxygen. Within the pulmonary system, nitric oxide can combine with oxygen and water to produce nitrogen dioxide and nitrite, respectively, which interact with oxyhaemoglobin to produce methaemoglobin and nitrate.

Thus, the end products of nitric oxide that enter the systemic circulation are predominantly methaemoglobin and nitrate.

Methaemoglobin disposition has been investigated as a function of time and nitric oxide exposure concentration in neonates with respiratory failure. Methaemoglobin concentrations increase during the first 8 hours of nitric oxide exposure. The mean methaemoglobin levels remained below 1% in the placebo group and in the 5 ppm and 20 ppm iNO groups, but reached approximately 5% in the 80 ppm iNO group. Methaemoglobin levels > 7% were attained only in patients receiving 80 ppm, where they comprised 35% of the group. The average time to reach peak methaemoglobin was 10 ± 9 (SD) hours (median, 8 hours) in these 13 patients; but one patient did not exceed 7% until 40 hours.

Nitrate has been identified as the predominant nitric oxide metabolite excreted in the urine, accounting for > 70% of the nitric oxide dose inhaled. Nitrate is cleared from the plasma by the kidney at rates approaching the rate of glomerular filtration.

• 5.3 Preclinical safety data

Effects seen in single and repeat dose-toxicity studies in rodents were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. Toxicity is related to anoxia resulting from elevated methaemoglobin levels.

No reproductive and developmental toxicity studies have been performed.

A battery of genotoxicity tests has demonstrated mutagenic potential of nitric oxide in some in vitro test systems and no clastogenic effect in the in vivo system. This is possibly related to the formation of mutagenic nitrosamines, DNA alterations or impairment of DNA repair mechanisms. A low incidence in uterine adenocarcinomas in rats following daily exposure to the recommended human dose for two years was tentatively considered treatment related.

The significance of these findings for clinical use in neonates and the potential for effects on the germ cells are unknown.

• 6. PHARMACEUTICAL PARTICULARS

  • 6.1 List of excipients

Nitrogen

• 6.2 Incompati­bilities

This medicinal product must not be mixed with other medicinal product/equip­ment/devices except those mentioned in section 6.6.

The following materials should not be used or be present in any equipment/device(s) used in nitric oxide administration : Butylrubber, Polyamide and Polyurethane.

• 6.3 Shelf life

• 1 year (2l gas cylinder) 3 years (10l gas cylinder)

• 6.4 Special precautions for storage

All regulations concerning handling of pressurised cylinders must be followed.

Storage is supervised by the specialists at the hospital. Cylinders are to be stored in well-ventilated rooms or in ventilated sheds where they are protected from rain and direct sunlight.

The cylinders must be stored at a temperature between –10 and +50°C.

Protect the cylinders from shocks, falls, oxidising and flammable materials, moisture, sources of heat or ignition.

Storage in the pharmacy department The gas cylinders should be kept in a place designated exclusively for medicinal gas storage that is well ventilated, clean and under lock and key. This place should house a separate, special facility for the storage of nitric oxide gas cylinders. Storage in medical department

The cylinder should be placed in an area with appropriate equipment to ensure that the cylinder is held vertically.

Transport of gas cylinders

The gas cylinders should be transported with appropriate material in order to protect them from the risk of shocks and falls.During inter- or within-hospital transfers of patients treated with Neophyr, the gas cylinders should be securely stowed away in order to hold the gas cylinders vertically and to avoid the risk of falls or untimely modifying output. Particular attention should be also turned to the fastening of the pressure regulator so as to avoid the risk of accidental failures.

Do not use Neophyr after the expiry date which is stated on the gas cylinder label. The expiry date refers to the last day of that month.

• 6.5 Nature and contents of container

Gas cylinders with a capacity of 2l.

A 2-liter gas cylinder filled to 150 bar contains about 0,35 kg of gas.

Or

Gas cylinders with a capacity of 10l.

A 10-liter gas cylinder filled to 150 bar contains about 1,77 kg of gas.

Aluminium alloy cylinders have a white painted body and a turquoise-painted shoulder.

They are equipped with a stainless steel residual pressure valve with a specific ISO 5145 (2004) type outlet connector.

Not all pack sizes may be marketed.

• 6.6 Special precautions for disposal

All equipment, including connectors, tubing and circuits, used in the delivery of nitric oxide must be made of materials compatible with the gas.

From a corrosion point of view the supply system can be divided into two zones:

• 1 ) From the gas cylinder valve to the humidifier (dry gas) and

• 2 ) From the humidifier to outlet (moist gas which may contain NO2).

Tests show that dry nitric oxide mixtures can be used with most materials. However, the presence of nitrogen dioxide and moisture creates an aggressive atmosphere. Among metallic construction materials, only stainless steel can be recommended. Tested polymers which can be used in nitric oxide administration systems include polyethylene (PE) and polypropylene (PP). Butyl rubber, polyamide, and polyurethane should not be used. Polytrifluorochlo­roethylene, hexafluoropropene-vinyliden copolymer and polytetraflou­rethylene have been used extensively with pure nitric oxide and other corrosive gases. They were considered so inert that testing was not required.

To avoid any incidents, the following instructions must be strictly adhered to:

• check that the equipment is in working order before use.
• firmly secure the cylinders using chains or hooks in the rack to avoid any accidental falls
• do not use if the cylinder pressure is below 10 bar
• never open a valve abruptly
• do not handle a cylinder on which the valve is not protected by a bonnet cap
• use a specific ISO 5145 (2004) connector: n°29 specific NO/N2 (100 ppm< NO < 1000 ppm) W30×2 15,2–20,8 DR
• at each new use, purge the pressure- reducer/ flowmeter 3 times using the nitric oxide/ nitrogen mixture
• do not attempt to repair a defective valve
• do not tighten the pressure-reducer/flowmeter using a gripper, otherwise the seal may be crushed and the administration device damaged
• evacuate exhaled gases outside (avoiding areas in which they may accumulate). Before use, it should be ensured that the room has the appropriate ventilation system for evacuating gases in the event of an accident or accidental leaks.
• as nitric oxide is colorless and odorless, it is recommended using a detection system in all rooms in which it is to be used or stored.
• personnel exposure limits (see section 4.2: Dosage and route of administration)

Instruction for cylinder disposal:

When the cylinder is empty, do not dispose of it. Empty cylinders will be collected by the supplier.

• 7. MARKETING AUTHORISATION HOLDER

SOL SpA – via Borgazzi 27, 20900 Monza (Italy)

• 8. MARKETING AUTHORISATION NUMBER(S)

Neophyr 225ppm: PA 1848/001/003 Neophyr 450ppm: PA 1848/001/002 Neophyr 1000ppm: PA1848/001/001

• 9. DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION

Date of first authorisation: 16/02/2012 Renewal of the authorisation: 16/02/2017

• 10. DATE OF REVISION OF THE TEXT